Biotech Values

[rkrw]

Everyone is asking about partnerships and he was guiding that he doesn't expect to sign a deal this year. He also let investors know their plans no longer include a worldwide partnership and they intend to retain as much rights to the compound as possible. How is communicating that a tactical error? The exact timing of a deal for 534 and how he manages investor expectations wouldn't be at the top of things I would worry about.